Literature DB >> 23040251

Radiologic imaging of patients with bladder cancer.

Andrei S Purysko1, Hilton M Leão Filho, Brian R Herts.   

Abstract

Imaging has an ancillary but important role in the detection, staging, and follow-up of bladder cancer. Computed tomography urography (CTU) has widely replaced intravenous urography (IVU) and is currently the imaging modality most commonly used for the initial evaluation of patients with or suspected of having bladder tumors, as CTU allows a fast and comprehensive evaluation of the urinary tract in a single exam. Magnetic resonance imaging (MRI) affords better soft tissue contrast, which allows for more accurate staging than can be achieved with other imaging modalities; the role of MRI in bladder cancer is expected to grow. Despite myriad technical advances, imaging of the bladder has several limitations and technical challenges. The performance of the common and some promising newer imaging modalities in the evaluation of bladder cancer are discussed.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23040251     DOI: 10.1053/j.seminoncol.2012.08.010

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  3 in total

1.  Diagnosis and treatment of extra-adrenal pheochromocytoma of urinary bladder: case report and literature review.

Authors:  Wei Li; Bin Yang; Jian-Ping Che; Yang Yan; Min Liu; Qian-Yu Li; Yuan-Yuan Zhang; Jun-Hua Zheng
Journal:  Int J Clin Exp Med       Date:  2013-09-25

Review 2.  Current role of PET, CT, MR for invasive bladder cancer.

Authors:  Nathan Lawrentschuk; Sze Ting Lee; Andrew M Scott
Journal:  Curr Urol Rep       Date:  2013-04       Impact factor: 3.092

3.  Clinical Evaluation of Tavocept to Decrease Diuresis Time and Volume in Dogs with Bladder Cancer Receiving Cisplatin.

Authors:  C J Henry; B K Flesner; S A Bechtel; J N Bryan; D J Tate; K A Selting; J C Lattimer; M E Bryan; L Grubb; F Hausheer
Journal:  J Vet Intern Med       Date:  2017-10-27       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.